_256_384.jpg)
Drug Approval | June 24, 2024
Cipla gets 6 observations from USFDA for Goa facility
The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time
The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
The consultative meet, a first of its kind, will bring together representatives from diverse domains of Traditional Medicine (TM) in India
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
As on 31st March 2024, Jubilant Pharmova Limited reported Gross Debt at Rs. 3,414 crore
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
